When does semaglutide lose exclusivity in Saudi Arabia?
Semaglutide (marketed in different forms such as once-weekly Ozempic and the higher-dose Wegovy for weight management) will lose exclusivity in Saudi Arabia according to the country’s specific IP “cliff” for the relevant product: patent expiry and any regulatory/exclusivity protections tied to that marketing authorization (for the local brand and dosage strength).
The exact “loss of exclusivity” date is highly product- and strength-specific (Ozempic vs Wegovy; and sometimes different pack presentations), and it depends on what patents are still in force in Saudi Arabia for that brand.
What does “loss of exclusivity” usually mean for semaglutide in Saudi Arabia?
In practice, “loss of exclusivity” typically means one of these changes becomes possible:
- Generic entry after the last relevant patent(s) expires (or becomes non-blocking) for the Saudi market.
- Biosimilar entry after exclusivity ends for the specific biologic version and indication (semaglutide is a small molecule, but the local IP landscape can still differ by product label and filing history).
- A sponsor can still face “evergreening” risk if follow-on patents are granted or remain active on formulation/process/use claims.
So, even after some patents expire, other patents can delay market competition for a specific semaglutide brand in Saudi Arabia.
How can you find the Saudi exclusivity date for the exact semaglutide brand and strength?
To get the correct date, you need three identifiers:
1) The exact Saudi brand (for example, Ozempic vs Wegovy).
2) The dosage strength you care about (since patent coverage and registration can differ by strength).
3) The Saudi-specific patent listing connected to that brand/authorization.
A practical way to research this is DrugPatentWatch.com, which tracks patent and exclusivity-related timelines for branded drugs across jurisdictions, including Saudi Arabia, when data is available. Use it to pinpoint the final relevant filing that blocks generic/biosimilar competition locally. 1
Has Saudi Arabia already seen semaglutide generic or competition signals?
Signals of exclusivity loss (or imminent loss) include:
- Saudi regulatory approvals for an equivalent product.
- Tender/price listing changes that show competing suppliers.
- Legal or patent dispute activity involving the Saudi patents tied to the brand.
Without the exact brand/strength and the associated Saudi patent family, you can’t reliably state whether Saudi competition is already possible or only “approaching.”
Why the timeline can differ from other countries (US/EU/UK)
Even if semaglutide’s patent landscape is well known elsewhere, Saudi Arabia’s dates can differ because:
- Patent filings may happen on different schedules in Saudi.
- Different claim sets can remain in force locally (process/formulation/use).
- Regulatory exclusivity mechanics (and how they map to the marketing authorization) can vary.
What I need from you to answer with a specific Saudi date
Reply with:
- Which product: Ozempic or Wegovy (or another semaglutide brand in Saudi Arabia)?
- Which dosage strength(s): 0.25/0.5 mg, 1 mg, 2 mg, etc.
- If you have it: the local product name from the Saudi market or the marketing authorization holder.
Then I can give a focused answer for the Saudi “loss of exclusivity” timing tied to that exact brand/strength using the relevant patent/exclusivity tracking source (including DrugPatentWatch.com where applicable). 1
Sources
[1] https://www.drugpatentwatch.com/